FOSTER CITY, Calif.--(BUSINESS WIRE)--OXIS International (OTCBB: OXIS) (Nouveau Marché: OXIS) (FWB: OXI), a biopharmaceutical company focused on commercializing research assays, nutraceutical and therapeutic products related to oxidative stress and, through its majority interest in BioCheck, a leading provider of high quality immunoassay clinical kits and contract services, today released a statement by its President and CEO Marvin S. Hausman MD about the future direction of the Company. Dr. Hausman’s statements were in response to questions from investors about Oxis International’s involvement in the rapidly growing field of developing and introducing early predictive biomarkers in clinical applications as reported in a Wall Street Journal article on December 15, 2006, entitled “The Rush to Biomarker Tests.”
